Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson Sells 6,256 Shares

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16. Following the transaction, the chief accounting officer now directly owns 19,241 shares in the company, valued at $483,141.51. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, October 3rd, Travis Alvin Thompson sold 153 shares of Bicycle Therapeutics stock. The shares were sold at an average price of $22.26, for a total value of $3,405.78.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC traded down $0.20 during trading on Wednesday, hitting $23.22. The company had a trading volume of 151,191 shares, compared to its average volume of 355,768. Bicycle Therapeutics plc has a 12 month low of $13.07 and a 12 month high of $28.67. The stock has a 50 day simple moving average of $24.55 and a 200 day simple moving average of $23.18. The firm has a market capitalization of $1.10 billion, a P/E ratio of -7.06 and a beta of 0.89.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. During the same quarter in the previous year, the business earned ($1.26) earnings per share. Bicycle Therapeutics’s quarterly revenue was down 50.0% on a year-over-year basis. As a group, analysts predict that Bicycle Therapeutics plc will post -3.01 EPS for the current year.

Analysts Set New Price Targets

BCYC has been the subject of a number of analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, September 16th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a research report on Thursday, October 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.13.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of BCYC. Price T Rowe Associates Inc. MD boosted its position in Bicycle Therapeutics by 45.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 401,646 shares of the company’s stock valued at $10,001,000 after buying an additional 124,809 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Bicycle Therapeutics by 13.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,038,917 shares of the company’s stock valued at $25,869,000 after acquiring an additional 121,613 shares in the last quarter. TD Asset Management Inc lifted its stake in shares of Bicycle Therapeutics by 76.7% during the 2nd quarter. TD Asset Management Inc now owns 97,186 shares of the company’s stock worth $1,967,000 after purchasing an additional 42,200 shares during the period. Perceptive Advisors LLC acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at $11,577,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Bicycle Therapeutics by 275.2% in the second quarter. The Manufacturers Life Insurance Company now owns 97,392 shares of the company’s stock worth $1,971,000 after acquiring an additional 71,434 shares in the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.